Terumo and Propofol Injectable

As indicated below in April 2016 Phosphagenics and Terumo entered into an 18 month arrangement for a propofol injectable development.This currently only leaves about 4 months for this agreement to run.According to Future Market Insights[FMI] propofol accounts for nearly one-third of the global anasthesia market and is expected to expand at CAGR of over 5% through 2025.

"As part of the R&D alliance the companies have also agreed to collaborate on the global development of three additional pharmaceutical products leveraging Phosphagenics’ proprietary TPM® technology: a TPM®/Propofol injection building on the prototype already developed at Phosphagenics and two additional novel TPM® containing pharmaceutical products"
Kens